HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Else Nutrition Takes 'Clean Label' Into Infant Formula, Toddler Beverage Market

Executive Summary

Else Nutrition will be one of the first companies to market baby and toddler formula and a children’s beverage without dairy or soy while containing a few core ingredients, says CEO Hamutal Yitzhak. Products will debut in North America and Europe in 2020.

You may also be interested in...



Requiring Infant Formula, Medical Food Shortage Updates Included In US FDA Budget Request

FDA’s justification report published with Biden administration’s FY2022 federal budget request includes $1.194bn for agency’s food programs, which include its oversight of supplement industry, up from $1.11bn in FY2021 appropriation.

Store Brand Cough/Cold OTCs, Alterna Conditioners Among Recent Recalls

Sun Pharmaceutical, P&L Developments and Preferred Pharmaceutical made OTCs for customers including CVS, Target and Walgreens. Latest updates to FDA recalls database also includes polypeptide- and colostrum-containing immunity support supplements made by APS BioGroup and Alterna anti-aging, moisture-replenishing conditioning milk and cream marketed by Henkel Corp.

Wellness Market News: Formula Fails Standards, CarnoSyn Trademark Infringement Alleged, More

Former FDA chief Kessler heads CSPI board; CRN-supported Rose Awards go to Ross, Das; Bobbie Baby infant formula fails FDA standards; CRN launches Retailer Relations Forum; and NAI alleges CarnoSyn trademark infringement by Vitalize.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

RS149412

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel